BSE Live
Jan 28, 13:47Prev. Close
1240.00
Open Price
1240.05
Bid Price (Qty.)
1223.30 (32)
Offer Price (Qty.)
1224.00 (200)
NSE Live
Jan 28, 13:47Prev. Close
1239.80
Open Price
1241.90
Bid Price (Qty.)
1223.60 (709)
Offer Price (Qty.)
1224.00 (884)
| Cash Flow of Dr Reddys Laboratories (in Rs. Cr.) | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 1,885.70 | 2,292.00 | 1,350.40 | 1,553.70 | 2,858.80 | |
| Net CashFlow From Operating Activities | 2,984.10 | 2,870.40 | 1,803.00 | 2,144.40 | 3,262.60 | |
| Net Cash Used In Investing Activities | -492.30 | -772.70 | -1,488.30 | -1,840.40 | -2,039.40 | |
| Net Cash Used From Financing Activities | -2,515.90 | -2,132.60 | -444.00 | -369.20 | -1,700.10 | |
| Foreign Exchange Gains / Losses | -2.50 | 3.50 | 5.70 | -49.10 | 429.50 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | -26.60 | -31.40 | -123.60 | -114.30 | -47.40 | |
| Cash And Cash Equivalents Begin of Year | 222.80 | 254.20 | 377.80 | 492.10 | 539.50 | |
| Cash And Cash Equivalents End Of Year | 196.20 | 222.80 | 254.20 | 377.80 | 492.10 |
22.01.2026
Dr Reddys Labs Consolidated December 2025 Net Sales at Rs 8,753.40 crore, up 4.44% Y-o-Y
22.01.2026
Dr Reddys Labs Standalone December 2025 Net Sales at Rs 4,282.70 crore, down 14.6% Y-o-Y
22.01.2026
16.01.2026
22.01.2026
Dr Reddys Labs Consolidated December 2025 Net Sales at Rs 8,753.40 crore, up 4.44% Y-o-Y
22.01.2026
Dr Reddys Labs Standalone December 2025 Net Sales at Rs 4,282.70 crore, down 14.6% Y-o-Y
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
28.10.2025
Dr Reddys Labs Consolidated September 2025 Net Sales at Rs 8,828.30 crore, up 9.83% Y-o-Y
22.01.2025
Dr Reddy's Labs Q3 Preview: Lower Revlimid contribution, subdued US sales to dent earnings growth
12.07.2023
Dr Reddys Laboratories Q1 PAT seen up 73.7% YoY to Rs 912.4 cr: Nirmal Bang
24.01.2023
Dr Reddy’s Q3 Preview | Sharp drop in net profit likely on slump in US revenues
27.10.2022
Dr Reddy’s Q2 preview: Pharma major likely to report sharp drop in net profit on weak US biz